<p>How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?</p> <p>Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm" target="_blank" rel= "noopener">https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu</a></p>

How Many Lymph Nodes Are Involved in This Patient With HR-Positive, HER2-Negative Early Breast Cancer?

Hear from experts as they discuss timely clinical topics as well as relevant and actionable strategies for practice improvement. This podcast is available for CME credit.